Codexis completes technology transfer to Teva
Two products transferred to pilot manufacturing and a third to full-scale production
Codexis has now successfully completed technology transfer of custom biocatalysts for the manufacture of three undisclosed pharmaceutical products to Teva Pharmaceutical Industries, the generic drug manufacturer.
Two products have been transferred to pilot manufacturing and a third to full-scale commercial manufacturing. The original agreements covering development of these processes were signed in 2009.
Teva is using Codexis biocatalysis technology to reengineer key process steps in the manufacture of the covered generic products. Codexis develops proprietary custom biocatalysts which can reduce pharmaceutical manufacturing development time and costs. Leading drug and chemical companies worldwide use Codexis technology.
Financial terms were not disclosed.
‘These are significant achievements in our relationship with Teva,’ said Joseph Sarret, senior vice president and chief business officer. ‘We are developing custom biocatalytic manufacturing processes for four Teva products, and the transfer to pilot and commercial manufacturing is important recognition of the cost savings and value-added technology that Codexis brings to the highly competitive generics marketplace.’
